Skip to main content
Erschienen in: Tumor Biology 1/2013

01.02.2013 | Research Article

Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population

verfasst von: Benyuan Deng, Fei Liu, Yonggang Wei, Limei Luo, Xi Chen, Lvnan Yan, Bo Li

Erschienen in: Tumor Biology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

P73, a p53 homolog, has some p53-like activities and plays an important role in modulating cell cycle, apoptosis, and DNA repair. A potentially functional dinucleotide polymorphism, G4C14-to-A4T14, has been identified in the 5′ untranslated region of exon 2 of the p73 gene, which may theoretically form a stem-loop structure and affect gene expression. We hypothesized that genetic variants in p73 may modify individual susceptibility to hepatocellular carcinoma (HCC). To test this hypothesis that these two common variants play a role in HCC susceptibility, we conducted a hospital-based case–control study of 476 HCC patients and 526 cancer-free controls in a Chinese population. The matrix-assisted laser desorption ionization time-of-flight mass spectrometry method was performed to detect these polymorphisms. The results showed that the genotype and allele frequencies of the p73 G4C14-A4T14 did not differ significantly between the HCC patients and the control group (all P values are above 0.05). However, with stratification analysis by age, sex, smoking status, drinking status, HBV carrier state, and family history of cancer, we found that the variant genotypes (GC/AT + AT/AT) of the p73 G4C14-A4T14 was associated with a significant increased risk of HCC among HbsAg-positive individuals (adjusted OR = 2.19, 95 % CI = 1.25–3.83) and among women (adjusted OR = 2.62, 95 % CI = 1.47, 4.66). These results suggest that the p73 G4C14-to-A4T14 dinucleotide polymorphism may play a role in the development of chronic HBV-infected HCC in the Chinese population, especially among women.
Literatur
1.
Zurück zum Zitat Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300–8.PubMedCrossRef Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300–8.PubMedCrossRef
2.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
Zurück zum Zitat Heneghan MA, Johnson PJ, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer. 2003;34:19–26.PubMedCrossRef Heneghan MA, Johnson PJ, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer. 2003;34:19–26.PubMedCrossRef
4.
Zurück zum Zitat Kato N, Ji G, Wang Y, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology. 2005;42:846–53.PubMedCrossRef Kato N, Ji G, Wang Y, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology. 2005;42:846–53.PubMedCrossRef
5.
Zurück zum Zitat Kim YJ, Lee HS. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology. 2005;48:10–5.PubMedCrossRef Kim YJ, Lee HS. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology. 2005;48:10–5.PubMedCrossRef
6.
Zurück zum Zitat Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404:99–103.PubMedCrossRef Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404:99–103.PubMedCrossRef
7.
Zurück zum Zitat Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560–4.PubMedCrossRef Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560–4.PubMedCrossRef
8.
Zurück zum Zitat Wang XQ, Ongkeko WM, Lau AW, et al. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res. 2001;61:1598–603.PubMed Wang XQ, Ongkeko WM, Lau AW, et al. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res. 2001;61:1598–603.PubMed
9.
10.
Zurück zum Zitat Cai YC, Yang GY, Nie Y, et al. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis. 2000;21:683–9.PubMedCrossRef Cai YC, Yang GY, Nie Y, et al. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis. 2000;21:683–9.PubMedCrossRef
11.
Zurück zum Zitat Mai M, Yokomizo A, Qian C, et al. Activation of p73 silent allele in lung cancer. Cancer Res. 1998;58:2347–9.PubMed Mai M, Yokomizo A, Qian C, et al. Activation of p73 silent allele in lung cancer. Cancer Res. 1998;58:2347–9.PubMed
12.
Zurück zum Zitat Nomoto S, Haruki N, Kondo M, et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 1998;58:1380–3.PubMed Nomoto S, Haruki N, Kondo M, et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 1998;58:1380–3.PubMed
13.
Zurück zum Zitat Takahashi H, Ichimiya S, Nimura Y, et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 1998;58:2076–7.PubMed Takahashi H, Ichimiya S, Nimura Y, et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 1998;58:2076–7.PubMed
14.
Zurück zum Zitat Peters MA, Janer M, Kolb S, et al. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate. 2001;48:292–6.PubMedCrossRef Peters MA, Janer M, Kolb S, et al. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate. 2001;48:292–6.PubMedCrossRef
15.
Zurück zum Zitat Li Q, Athan ES, Wei M, et al. TP73 allelic expression in human brain and allele frequencies in Alzheimer’s disease. BMC Med Genet. 2004;5:14.PubMedCrossRef Li Q, Athan ES, Wei M, et al. TP73 allelic expression in human brain and allele frequencies in Alzheimer’s disease. BMC Med Genet. 2004;5:14.PubMedCrossRef
16.
Zurück zum Zitat Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1q36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–19.PubMedCrossRef Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1q36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–19.PubMedCrossRef
17.
Zurück zum Zitat Hu Z, Miao X, Ma H, et al. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer. 2005;114:455–60.PubMedCrossRef Hu Z, Miao X, Ma H, et al. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer. 2005;114:455–60.PubMedCrossRef
18.
Zurück zum Zitat Hamajima N, Matsuo K, Suzuki T, et al. No association of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphism with the risk of digestive tract cancers in Japanese. Cancer Lett. 2002;181:81–5.PubMedCrossRef Hamajima N, Matsuo K, Suzuki T, et al. No association of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphism with the risk of digestive tract cancers in Japanese. Cancer Lett. 2002;181:81–5.PubMedCrossRef
19.
Zurück zum Zitat Hiraki A, Matsuo K, Hamajima N, et al. Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. Asian Pac J Cancer Prev. 2003;4:107–12.PubMed Hiraki A, Matsuo K, Hamajima N, et al. Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. Asian Pac J Cancer Prev. 2003;4:107–12.PubMed
20.
Zurück zum Zitat Huang XE, Hamajima N, Katsuda N, et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2000;10:307–11.CrossRef Huang XE, Hamajima N, Katsuda N, et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2000;10:307–11.CrossRef
21.
Zurück zum Zitat Niwa Y, Hirose K, Matsuo K, et al. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett. 2005;219:183–90.PubMedCrossRef Niwa Y, Hirose K, Matsuo K, et al. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett. 2005;219:183–90.PubMedCrossRef
22.
Zurück zum Zitat Li G, Sturgis EM, Wang LE, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2004;25:1911–6.PubMedCrossRef Li G, Sturgis EM, Wang LE, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2004;25:1911–6.PubMedCrossRef
23.
Zurück zum Zitat Kang S, Wang DJ, Li WS, et al. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int J Gynecol Cancer. 2009;19:572–7.PubMedCrossRef Kang S, Wang DJ, Li WS, et al. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int J Gynecol Cancer. 2009;19:572–7.PubMedCrossRef
24.
Zurück zum Zitat Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res. 2004;2:371–86.PubMed Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res. 2004;2:371–86.PubMed
25.
Zurück zum Zitat Pozniak CD, Radinovic S, Yang A, et al. An anti-apoptotic role of the p53 family member, p73, during developmental neuron death. Science. 2000;289:304–6.PubMedCrossRef Pozniak CD, Radinovic S, Yang A, et al. An anti-apoptotic role of the p53 family member, p73, during developmental neuron death. Science. 2000;289:304–6.PubMedCrossRef
26.
Zurück zum Zitat Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci. 2005;96:729–37.PubMedCrossRef Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci. 2005;96:729–37.PubMedCrossRef
27.
Zurück zum Zitat Arfaoui AT, Ben Mahmoud LK, Ben Hmida A, et al. Relationship between p73 polymorphism and the immunohistochemical profile of the full-length (TAp73) and NH2-truncated (ΔNp73) isoforms in Tunisian patients. Appl Immunohistochem Mol Morphol. 2010;18:546–54.PubMedCrossRef Arfaoui AT, Ben Mahmoud LK, Ben Hmida A, et al. Relationship between p73 polymorphism and the immunohistochemical profile of the full-length (TAp73) and NH2-truncated (ΔNp73) isoforms in Tunisian patients. Appl Immunohistochem Mol Morphol. 2010;18:546–54.PubMedCrossRef
28.
Zurück zum Zitat Li G, Wang LE, Chamberlain RM, et al. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res. 2004;64:6863–6.PubMedCrossRef Li G, Wang LE, Chamberlain RM, et al. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res. 2004;64:6863–6.PubMedCrossRef
29.
Zurück zum Zitat Wang X, Zhang X, Qiu B, et al. MDM2 SNP309T > G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32:1172–8.PubMedCrossRef Wang X, Zhang X, Qiu B, et al. MDM2 SNP309T > G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32:1172–8.PubMedCrossRef
30.
Zurück zum Zitat Li LM, Zeng XY, Ji L, et al. Association of XPC and XPG polymorphisms with the risk of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2010;18:271–5.PubMed Li LM, Zeng XY, Ji L, et al. Association of XPC and XPG polymorphisms with the risk of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2010;18:271–5.PubMed
31.
Zurück zum Zitat Ryan BM, McManus R, Daly JS, et al. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer. 2001;85:1499–503.PubMedCrossRef Ryan BM, McManus R, Daly JS, et al. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer. 2001;85:1499–503.PubMedCrossRef
32.
Zurück zum Zitat Ge H, Wang YM, Cao YY, et al. The p73 polymorphisms are not associated with susceptibility to esophageal squamous cell carcinoma in a high incidence region of China. Dis Esophagus. 2007;20:290–6.PubMedCrossRef Ge H, Wang YM, Cao YY, et al. The p73 polymorphisms are not associated with susceptibility to esophageal squamous cell carcinoma in a high incidence region of China. Dis Esophagus. 2007;20:290–6.PubMedCrossRef
Metadaten
Titel
Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population
verfasst von
Benyuan Deng
Fei Liu
Yonggang Wei
Limei Luo
Xi Chen
Lvnan Yan
Bo Li
Publikationsdatum
01.02.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0550-9

Weitere Artikel der Ausgabe 1/2013

Tumor Biology 1/2013 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.